$AZN Company News Drug makers face another $65
Post# of 145492
Posted On: 12/19/2014 12:53:48 PM
$AZN Company News
Drug makers face another $65 billion patent cliff 12:42 p.m. Dec. 10, 2014 - Russ Britt
Eli Lilly, AstraZeneca launch patient trial for Alzheimer's treatment 7:19 a.m. Dec. 1, 2014 - Tomi Kilgore
AstraZeneca advances in London; pound rises as inflation ticks up 11:59 a.m. Nov. 18, 2014 - Carla Mozee
AstraZeneca forecasts revenue of $45 bln by 2023 2:43 a.m. Nov. 18, 2014 - MarketWatch.com
FDA revokes Ranbaxy’s right to generic versions of Nexium, Valcyte 11:05 a.m. Nov. 6, 2014 - Sean McLain
AstraZeneca lifts 2014 guidance as profit slides 2:33 a.m. Nov. 6, 2014 - MarketWatch.com
Pfizer sales fall less than expected 6:34 a.m. Oct. 28, 2014 - MarketWatch.com
Eli Lilly's sales hit again by patent expirations 5:59 a.m. Oct. 23, 2014 - MarketWatch.com
3 stocks Ken Fisher likes 10:09 a.m. Oct. 21, 2014 - Insider Monkey
FTSE 100 teetering on edge of correction; Shire sinks in London 12:13 p.m. Oct. 15, 2014 - Carla Mozee
Is the AbbVie-Shire deal dead? Stock market thinks so 6:05 a.m. Oct. 15, 2014 - Sara Sjolin
FTSE 100 falls amid broader European selloff 11:02 a.m. Oct. 7, 2014 - Sara Sjolin
TNT Express slumps; Rio Tinto climbs: Europe’s stock movers 11:12 a.m. Sept. 24, 2014 - Sara Sjolin
Rio Tinto, Vodafone lift FTSE 100 for first day in three 11:11 a.m. Sept. 24, 2014 - Sara Sjolin
Pfizer held takeover talks with Actavis 12:33 a.m. Sept. 24, 2014 - Jonathan D. Rockoff
CF Industries rises on merger talks; AstraZeneca, AbbVie fall 2:21 p.m. Sept. 23, 2014 - Sue Chang
Burger King, AbbVie among stocks hit by new tax inversion rules 1:41 p.m. Sept. 23, 2014 - Ben Eisen
Eli Lilly agrees to co-develop AstraZeneca's Alzheimer's treatment 6:17 a.m. Sept. 16, 2014 - Tomi Kilgore
Lilly to pay AstraZeneca up to $500 mln as part of Alzheimer's treatment agreement 6:04 a.m. Sept. 16, 2014 - Tomi Kilgore
Eli Lilly, AstraZeneca agree to co-develop Alzheimer's treatment 6:03 a.m. Sept. 16, 2014 - Tomi Kilgore
Update: AstraZeneca Wins EU Approval For Lynparza 1:13 a.m. Today - Seeking Alpha
Tax Inversions Wrap Up 3:01 p.m. Dec. 18, 2014 - Seeking Alpha
AstraZeneca cancer drug cleared in Europe 7:22 a.m. Dec. 18, 2014 - Seeking Alpha
Is A Dividend Cut The End Of The World? Analysis Of Dividend-Cutting Companies, Part I 6:04 p.m. Dec. 17, 2014 - Seeking Alpha
Meet 5 Big Tech Stocks Expected To See Profits Surge 8:03 p.m. Dec. 16, 2014 - Investors Business Daily
Theravance Biopharma Pipeline Valuation 7:43 a.m. Dec. 16, 2014 - Seeking Alpha
Money flow surges in AstraZeneca 10:38 a.m. Dec. 11, 2014 - Seeking Alpha
Nektar/AstraZeneca's Moventig Gets EU Approval for OIC - Analyst Blog 6:50 p.m. Dec. 10, 2014 - Zacks.com
Merck's Keytruda Might Treat Virulent Breast Cancer 10:04 a.m. Dec. 10, 2014 - Investors Business Daily
AstraZeneca (AZN) Moving On Heavy Volume In The Pre-Market Hours 9:24 a.m. Dec. 10, 2014 - TheStreet.com
Biggest Movers in Healthcare Stocks Now – NBIX TECH AZN ISIS 7:30 a.m. Dec. 10, 2014 - InvestorPlace.com
Dynavax & AstraZeneca Alter Agreement for Asthma Product - Analyst Blog 6:20 p.m. Dec. 9, 2014 - Zacks.com
Update: AstraZeneca Wins EU Approval For Moventig 2:46 p.m. Dec. 9, 2014 - Seeking Alpha
Take the Risk for Reward With Pfizer Options 9:00 a.m. Dec. 9, 2014 - InvestorPlace.com
Moventig cleared in Europe for OIC 7:14 a.m. Dec. 9, 2014 - Seeking Alpha
Actavis' Antibiotic Backed for FDA Approval, Response in Q1 - Analyst Blog 6:30 p.m. Dec. 8, 2014 - Zacks.com
Assessing The Magnitude Of Pfizer's Coming Dividend Increase 3:11 p.m. Dec. 8, 2014 - Seeking Alpha
Seattle Genetics down on ASH presentations 12:37 p.m. Dec. 8, 2014 - Seeking Alpha
Dynavax to initiate asthma trial 10:55 a.m. Dec. 8, 2014 - Seeking Alpha
Time To Focus On What's Good 4:59 p.m. Dec. 7, 2014 - Seeking Alpha
Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1™ Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4:01 p.m. Dec. 11, 2014 - PR Newswire - PRF
Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4:01 p.m. Nov. 25, 2014 - PR Newswire - PRF
AstraZeneca Announces Plans to Expand its Frederick, Maryland Biologics Manufacturing Center 11:08 a.m. Nov. 21, 2014 - BusinessWire - BZX
Global Oncology Market to hit $109 billion - Spotlight on Drug Life Cycle Management, M&A and Pipeline Strategies 11:37 a.m. Nov. 19, 2014 - PR Newswire - PRF
Cancer Diagnostics Market (Tumor Biomarker Tests, Imaging, Endoscopy and Biopsy) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020 1:33 p.m. Nov. 18, 2014 - PR Newswire - PRF
AstraZeneca Presents Data from Phase III Studies of Lesinurad in Combination with Allopurinol in Gout Patients at American College of Rheumatology 2014 Annual Meeting 9:00 a.m. Nov. 16, 2014 - BusinessWire - BZX
Cleveland Biolabs; A Diverse Play on Both Biodefense and Cancer 10:51 a.m. Nov. 13, 2014 - ACCESSWIRE
Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4:01 p.m. Nov. 11, 2014 - PR Newswire - PRF
Pharma Equities Technical Data - Salix Pharma, AstraZeneca, Novartis, Impax Laboratories, and Novo Nordisk 9:05 a.m. Nov. 11, 2014 - PR Newswire - PRF
U.S. FDA Approves Once-Daily XIGDUO™ XR Tablets for Adults with Type 2 Diabetes 6:05 a.m. Oct. 30, 2014 - BusinessWire - BZX
Global Pediatric Drugs and Vaccines Market 4:08 p.m. Oct. 23, 2014 - PR Newswire - PRF
Ardelyx's Tenapanor Selected for Oral and Poster Presentations at the American Society of Nephrology's Kidney Week 2014 9:30 a.m. Oct. 23, 2014 - PR Newswire - PRF
AstraZeneca Launches Fit2Me™, a Free Customized Diet and Lifestyle Support Program for People with Type 2 Diabetes 6:31 a.m. Oct. 15, 2014 - BusinessWire - BZX
Branding Campaign, Asset Sale, Executive Promotion, Clinical Data Presentation, and Drug Approval Update - Research Reports on Synchrony Financial, Avalonbay, Aflac, Teva and AstraZeneca 7:35 a.m. Oct. 7, 2014 - PR Newswire - PRF
Technical Updates on Health Care Sector Stocks - AstraZeneca, Novartis, Salix Pharma, Inovio Pharma, and CTI BioPharma 8:15 a.m. Oct. 6, 2014 - PR Newswire - PRF
Actor James Van Der Beek and AstraZeneca Join Forces to Educate Families about Influenza 10:34 a.m. Sept. 15, 2014 - PR Newswire - PRF
Actor James Van Der Beek and AstraZeneca Join Forces to Educate Families about Influenza 7:09 a.m. Sept. 15, 2014 - PR Newswire - PRF
Publishing of Clinical Study Data, Employee Recognition, Market Activity, Investment in Infrastructure - Research Reports on AstraZeneca, Northrop Grumman, Corning, PPL Corp. and Edison 8:10 a.m. Sept. 11, 2014 - PR Newswire - PRF
Trialbee Helps AstraZeneca Reduce the Time Required for Recruitment of Patients to Clinical Trials 6:32 a.m. Sept. 10, 2014 - BusinessWire - BZX
Favourable Rulings, Upcoming Conferences, Clinical Study Results, Drug Availability, and Tender Offers - Research Reports on United Therapeutics, Illumina, AstraZeneca, Eli Lilly and Abbott 8:20 a.m. Sept. 3, 2014 - PR Newswire - PRF
Drug makers face another $65 billion patent cliff 12:42 p.m. Dec. 10, 2014 - Russ Britt
Eli Lilly, AstraZeneca launch patient trial for Alzheimer's treatment 7:19 a.m. Dec. 1, 2014 - Tomi Kilgore
AstraZeneca advances in London; pound rises as inflation ticks up 11:59 a.m. Nov. 18, 2014 - Carla Mozee
AstraZeneca forecasts revenue of $45 bln by 2023 2:43 a.m. Nov. 18, 2014 - MarketWatch.com
FDA revokes Ranbaxy’s right to generic versions of Nexium, Valcyte 11:05 a.m. Nov. 6, 2014 - Sean McLain
AstraZeneca lifts 2014 guidance as profit slides 2:33 a.m. Nov. 6, 2014 - MarketWatch.com
Pfizer sales fall less than expected 6:34 a.m. Oct. 28, 2014 - MarketWatch.com
Eli Lilly's sales hit again by patent expirations 5:59 a.m. Oct. 23, 2014 - MarketWatch.com
3 stocks Ken Fisher likes 10:09 a.m. Oct. 21, 2014 - Insider Monkey
FTSE 100 teetering on edge of correction; Shire sinks in London 12:13 p.m. Oct. 15, 2014 - Carla Mozee
Is the AbbVie-Shire deal dead? Stock market thinks so 6:05 a.m. Oct. 15, 2014 - Sara Sjolin
FTSE 100 falls amid broader European selloff 11:02 a.m. Oct. 7, 2014 - Sara Sjolin
TNT Express slumps; Rio Tinto climbs: Europe’s stock movers 11:12 a.m. Sept. 24, 2014 - Sara Sjolin
Rio Tinto, Vodafone lift FTSE 100 for first day in three 11:11 a.m. Sept. 24, 2014 - Sara Sjolin
Pfizer held takeover talks with Actavis 12:33 a.m. Sept. 24, 2014 - Jonathan D. Rockoff
CF Industries rises on merger talks; AstraZeneca, AbbVie fall 2:21 p.m. Sept. 23, 2014 - Sue Chang
Burger King, AbbVie among stocks hit by new tax inversion rules 1:41 p.m. Sept. 23, 2014 - Ben Eisen
Eli Lilly agrees to co-develop AstraZeneca's Alzheimer's treatment 6:17 a.m. Sept. 16, 2014 - Tomi Kilgore
Lilly to pay AstraZeneca up to $500 mln as part of Alzheimer's treatment agreement 6:04 a.m. Sept. 16, 2014 - Tomi Kilgore
Eli Lilly, AstraZeneca agree to co-develop Alzheimer's treatment 6:03 a.m. Sept. 16, 2014 - Tomi Kilgore
Update: AstraZeneca Wins EU Approval For Lynparza 1:13 a.m. Today - Seeking Alpha
Tax Inversions Wrap Up 3:01 p.m. Dec. 18, 2014 - Seeking Alpha
AstraZeneca cancer drug cleared in Europe 7:22 a.m. Dec. 18, 2014 - Seeking Alpha
Is A Dividend Cut The End Of The World? Analysis Of Dividend-Cutting Companies, Part I 6:04 p.m. Dec. 17, 2014 - Seeking Alpha
Meet 5 Big Tech Stocks Expected To See Profits Surge 8:03 p.m. Dec. 16, 2014 - Investors Business Daily
Theravance Biopharma Pipeline Valuation 7:43 a.m. Dec. 16, 2014 - Seeking Alpha
Money flow surges in AstraZeneca 10:38 a.m. Dec. 11, 2014 - Seeking Alpha
Nektar/AstraZeneca's Moventig Gets EU Approval for OIC - Analyst Blog 6:50 p.m. Dec. 10, 2014 - Zacks.com
Merck's Keytruda Might Treat Virulent Breast Cancer 10:04 a.m. Dec. 10, 2014 - Investors Business Daily
AstraZeneca (AZN) Moving On Heavy Volume In The Pre-Market Hours 9:24 a.m. Dec. 10, 2014 - TheStreet.com
Biggest Movers in Healthcare Stocks Now – NBIX TECH AZN ISIS 7:30 a.m. Dec. 10, 2014 - InvestorPlace.com
Dynavax & AstraZeneca Alter Agreement for Asthma Product - Analyst Blog 6:20 p.m. Dec. 9, 2014 - Zacks.com
Update: AstraZeneca Wins EU Approval For Moventig 2:46 p.m. Dec. 9, 2014 - Seeking Alpha
Take the Risk for Reward With Pfizer Options 9:00 a.m. Dec. 9, 2014 - InvestorPlace.com
Moventig cleared in Europe for OIC 7:14 a.m. Dec. 9, 2014 - Seeking Alpha
Actavis' Antibiotic Backed for FDA Approval, Response in Q1 - Analyst Blog 6:30 p.m. Dec. 8, 2014 - Zacks.com
Assessing The Magnitude Of Pfizer's Coming Dividend Increase 3:11 p.m. Dec. 8, 2014 - Seeking Alpha
Seattle Genetics down on ASH presentations 12:37 p.m. Dec. 8, 2014 - Seeking Alpha
Dynavax to initiate asthma trial 10:55 a.m. Dec. 8, 2014 - Seeking Alpha
Time To Focus On What's Good 4:59 p.m. Dec. 7, 2014 - Seeking Alpha
Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1™ Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4:01 p.m. Dec. 11, 2014 - PR Newswire - PRF
Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4:01 p.m. Nov. 25, 2014 - PR Newswire - PRF
AstraZeneca Announces Plans to Expand its Frederick, Maryland Biologics Manufacturing Center 11:08 a.m. Nov. 21, 2014 - BusinessWire - BZX
Global Oncology Market to hit $109 billion - Spotlight on Drug Life Cycle Management, M&A and Pipeline Strategies 11:37 a.m. Nov. 19, 2014 - PR Newswire - PRF
Cancer Diagnostics Market (Tumor Biomarker Tests, Imaging, Endoscopy and Biopsy) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020 1:33 p.m. Nov. 18, 2014 - PR Newswire - PRF
AstraZeneca Presents Data from Phase III Studies of Lesinurad in Combination with Allopurinol in Gout Patients at American College of Rheumatology 2014 Annual Meeting 9:00 a.m. Nov. 16, 2014 - BusinessWire - BZX
Cleveland Biolabs; A Diverse Play on Both Biodefense and Cancer 10:51 a.m. Nov. 13, 2014 - ACCESSWIRE
Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4:01 p.m. Nov. 11, 2014 - PR Newswire - PRF
Pharma Equities Technical Data - Salix Pharma, AstraZeneca, Novartis, Impax Laboratories, and Novo Nordisk 9:05 a.m. Nov. 11, 2014 - PR Newswire - PRF
U.S. FDA Approves Once-Daily XIGDUO™ XR Tablets for Adults with Type 2 Diabetes 6:05 a.m. Oct. 30, 2014 - BusinessWire - BZX
Global Pediatric Drugs and Vaccines Market 4:08 p.m. Oct. 23, 2014 - PR Newswire - PRF
Ardelyx's Tenapanor Selected for Oral and Poster Presentations at the American Society of Nephrology's Kidney Week 2014 9:30 a.m. Oct. 23, 2014 - PR Newswire - PRF
AstraZeneca Launches Fit2Me™, a Free Customized Diet and Lifestyle Support Program for People with Type 2 Diabetes 6:31 a.m. Oct. 15, 2014 - BusinessWire - BZX
Branding Campaign, Asset Sale, Executive Promotion, Clinical Data Presentation, and Drug Approval Update - Research Reports on Synchrony Financial, Avalonbay, Aflac, Teva and AstraZeneca 7:35 a.m. Oct. 7, 2014 - PR Newswire - PRF
Technical Updates on Health Care Sector Stocks - AstraZeneca, Novartis, Salix Pharma, Inovio Pharma, and CTI BioPharma 8:15 a.m. Oct. 6, 2014 - PR Newswire - PRF
Actor James Van Der Beek and AstraZeneca Join Forces to Educate Families about Influenza 10:34 a.m. Sept. 15, 2014 - PR Newswire - PRF
Actor James Van Der Beek and AstraZeneca Join Forces to Educate Families about Influenza 7:09 a.m. Sept. 15, 2014 - PR Newswire - PRF
Publishing of Clinical Study Data, Employee Recognition, Market Activity, Investment in Infrastructure - Research Reports on AstraZeneca, Northrop Grumman, Corning, PPL Corp. and Edison 8:10 a.m. Sept. 11, 2014 - PR Newswire - PRF
Trialbee Helps AstraZeneca Reduce the Time Required for Recruitment of Patients to Clinical Trials 6:32 a.m. Sept. 10, 2014 - BusinessWire - BZX
Favourable Rulings, Upcoming Conferences, Clinical Study Results, Drug Availability, and Tender Offers - Research Reports on United Therapeutics, Illumina, AstraZeneca, Eli Lilly and Abbott 8:20 a.m. Sept. 3, 2014 - PR Newswire - PRF
(0)
(0)